So by January of 2017 Merck will know if anacetrapip is successful in boasting HDL. Other companies have given up on their CEPT trials.

Given that anacetrapip boasted HDL by 150% in their non blind trial of 1600+ patients it seems impressive but I guess that depends on what 150% actually means. For example does it move HDL up to what are considered healthy levels? The second question will be does it reduce MACE? If it does, then it seems to imply that rvx-208 will have competitor of perhaps anacetrapip applies to a different population than rvx-208???????

Either way, Merck will know much sooner than we will know about BETonMACE.

Toinv